Morbidity in an adenosine deaminase-deficient patient during 27 years of enzyme replacement therapy
Copyright © 2019 Elsevier Inc. All rights reserved.
| Veröffentlicht in: | Clinical immunology (Orlando, Fla.). - 1999. - 211(2020) vom: 28. Feb., Seite 108321 |
|---|---|
| 1. Verfasser: | |
| Weitere Verfasser: | , , , , , , , , |
| Format: | Online-Aufsatz |
| Sprache: | English |
| Veröffentlicht: |
2020
|
| Zugriff auf das übergeordnete Werk: | Clinical immunology (Orlando, Fla.) |
| Schlagworte: | Case Reports Journal Article Research Support, Non-U.S. Gov't Adenosine deaminase deficiency Enzyme replacement therapy Gene therapy Long-term Lymphoma Mycobacterium genavense PEG mehr... |
| Zusammenfassung: | Copyright © 2019 Elsevier Inc. All rights reserved. INTRODUCTION: Adenosine deaminase (ADA) deficiency causes severe immunodeficiency that is lethal in infancy. Enzyme replacement therapy (ERT) can improve the metabolic, immune and non-immune abnormalities in patients prior to transplantation, however, its benefits over extended periods are not well characterized. We describe a 28-year-old female who received ERT for 27 years. She suffered from EBV negative B cell lymphoma of the hip at 14 years of age and Guillian-Barre Syndrome 2 years later. At 22 years of age, she experienced a gastrointestinal infection with Mycobacterium genavense. At 26 years of age, lymphoma reoccurred with multiple liver lesions followed by Mycobacterium genavense infection with dissemination to the brain. Throughout this period, ADA activity in the plasma was within the therapeutic range. Repeated evaluations demonstrated very low lymphocyte counts and impaired T cell function CONCLUSIONS: ERT might be insufficient to maintain normal immunity over extended periods in some ADA-deficient patients |
|---|---|
| Beschreibung: | Date Completed 04.08.2020 Date Revised 04.08.2020 published: Print-Electronic Citation Status MEDLINE |
| ISSN: | 1521-7035 |
| DOI: | 10.1016/j.clim.2019.108321 |